Ecallantide is a highly active plasma kallikrein inhibitors that block the binding site of kallikrein to prevent cleavage of high molecular weight kininogen and subsequent bradykinin generation, and was shown to be efficacious for hereditary angioedema (HAE) attacks [25]. Here, KLK4 is linked to hereditary angioedema.